Literature DB >> 2865028

Effects of betaxolol, propranolol, and atenolol on isoproterenol-induced beta-adrenoceptor responses.

J G Riddell, R G Shanks.   

Abstract

Five healthy young men received, in a double-blind fashion, single oral doses of 10 mg betaxolol, 40 mg betaxolol, 50 mg atenolol, 40 mg propranolol, and placebo. After the dose each received serial 12-minute infusions of isoproterenol sulfate through the dose range 0.5 to 32 micrograms/min until the heart rate rose by 40 bpm or the subject could not tolerate the effects of the infusion. Heart rate, finger tremor, blood pressure, and forearm blood flow were measured after each infusion. Dose-response curves were constructed for the changes in these parameters with increasing doses of isoproterenol. The ascending order of potency of the drugs in preventing the changes in heart rate, finger tremor, diastolic blood pressure, forearm blood flow, and forearm vascular resistance induced by isoproterenol was placebo, 10 mg betaxolol, 50 mg atenolol, 40 mg betaxolol, and 40 mg propranolol. The ascending order of potency of the drugs in preventing the change in systolic blood pressure induced by isoproterenol was placebo, 10 mg betaxolol, 50 mg atenolol, 40 mg propranolol, and 40 mg betaxolol. Betaxolol, 10 mg, is equally cardioselective to 50 mg atenolol and at a dose of 40 mg betaxolol also exhibits cardioselectivity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2865028     DOI: 10.1038/clpt.1985.223

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

1.  The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

3.  The effects of time and dose on the relative beta 1- and beta 2-adrenoceptor antagonism of betaxolol and atenolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

Review 4.  Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.

Authors:  M M Buckley; K L Goa; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

Review 5.  Betaxolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension.

Authors:  R Beresford; R C Heel
Journal:  Drugs       Date:  1986-01       Impact factor: 9.546

Review 6.  Beta-blocker therapy and the risk of anaphylaxis.

Authors:  J H Toogood
Journal:  CMAJ       Date:  1987-05-01       Impact factor: 8.262

7.  Characterization of the beta-adrenoreceptors which mediate the isoprenaline-induced changes in finger tremor and cardiovascular function in man.

Authors:  T H Pringle; J G Riddell; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Controlled-release metoprolol compared with atenolol in asthmatic patients: interaction with terbutaline.

Authors:  C G Löfdahl; C Dahlöf; G Westergren; B Olofsson; N Svedmyr
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

9.  The assessment of the beta-adrenoceptor blocking activity and cardioselectivity of Koe 3290 in normal subjects.

Authors:  T H Pringle; A J McNeill; J G Riddell; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

10.  A dose-ranging study to evaluate the beta-adrenoceptor selectivity of single doses of betaxolol.

Authors:  N A Irvine; B J Lipworth; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.